The new meta-analysis in JACC: Cardiovascular Imaging confirms Cardiac magnetic resonance (CMR) imaging is an especially effective tool for evaluating patients with pulmonary arterial hypertension (PAH).
The researchers concluded that 鈥淐MR can predict clinical worsening, in addition to confirming its prognostic role, in a large cohort of patients with PAH.
"This study provides a strong rationale for considering CMR as a clinical trial endpoint.鈥
They added, too, that 鈥渙ur findings highlight the clinical utility of CMR imaging and support further evaluation of this modality as a clinically meaningful trial endpoint for the assessment of new therapies for PAH.鈥
Elsewhere in the news
- , Cardiovascular Business
- , MedPage Today
- , Science Direct
Article
(JACC: Cardiovascular Imaging) S. Alabed, Y. Shahin, P. Garg, F. Alandejani, C. S. Johns, R. A. Lewis, R. Condliffe, J. M. Wild, D. G. Kiely, A. J. Swift
